Literature DB >> 13677483

Classification of HIV protease inhibitors on the basis of their antiviral potency using radial basis function neural networks.

S J Patankar1, P C Jurs.   

Abstract

HIV protease inhibitors are being used as frontline therapy in the treatment of HIV patients. Multi-drug-resistant HIV mutant strains are emerging with the initial aggressive multi-drug treatment of HIV patients. This necessitates continued search for novel inhibitors of viral replication. These protease inhibitors may further be useful as pharmacological agents for inhibition of other viral replication. Classification models of HIV Protease inhibitors are developed using a data set of 123 compounds containing several heterocycles. Their inhibitory concentrations expressed as log (IC50) ranged from -1.52 to 2.12 log units. The dataset was divided into active and inactive classes on the basis of their antiviral potency. Initially a two-class problem (active, inactive) is explored using k-nearest neighbor approach. In order to introduce non-linearity in the classifier different approaches were investigated. This led to the goal of a fast, simple, minimum user input, radial basis function neural network (RBFNN) classifier development. Then the same two-class problem was resolved using the (RBFNN) classifier. A genetic algorithm with RBFNN fitness evaluator was used to search for the optimum descriptor subsets. The application of majority rules was also tested for the RBFNN classification. The best six descriptor model found by the new cost function showed predictive ability in the high 80% range for an external prediction set.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13677483     DOI: 10.1023/a:1025317806473

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  18 in total

1.  Heterocyclic HIV-1 protease inhibitors.

Authors:  P W Baures
Journal:  Org Lett       Date:  1999-07-29       Impact factor: 6.005

2.  Effective Backpropagation Training with Variable Stepsize.

Authors:  George S. Androulakis; Michael N. Vrahatis; George D. Magoulas
Journal:  Neural Netw       Date:  1997-01

3.  Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.

Authors:  S E Hagen; J V Prasad; F E Boyer; J M Domagala; E L Ellsworth; C Gajda; H W Hamilton; L J Markoski; B A Steinbaugh; B D Tait; E A Lunney; P J Tummino; D Ferguson; D Hupe; C Nouhan; S J Gracheck; J M Saunders; S VanderRoest
Journal:  J Med Chem       Date:  1997-11-07       Impact factor: 7.446

4.  Three learning phases for radial-basis-function networks.

Authors:  F Schwenker; H A Kestler; G Palm
Journal:  Neural Netw       Date:  2001-05

5.  4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.

Authors:  B D Tait; S Hagen; J Domagala; E L Ellsworth; C Gajda; H W Hamilton; J V Prasad; D Ferguson; N Graham; D Hupe; C Nouhan; P J Tummino; C Humblet; E A Lunney; A Pavlovsky; J Rubin; S J Gracheck; E T Baldwin; T N Bhat; J W Erickson; S V Gulnik; B Liu
Journal:  J Med Chem       Date:  1997-11-07       Impact factor: 7.446

6.  Discovery and optimization of nonpeptide HIV-1 protease inhibitors.

Authors:  P J Tummino; J V Prasad; D Ferguson; C Nouhan; N Graham; J M Domagala; E Ellsworth; C Gajda; S E Hagen; E A Lunney; K S Para; B D Tait; A Pavlovsky; J W Erickson; S Gracheck; T J McQuade; D J Hupe
Journal:  Bioorg Med Chem       Date:  1996-09       Impact factor: 3.641

7.  Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome.

Authors:  H Valdez; M M Lederman; I Woolley; C J Walker; L T Vernon; A Hise; B M Gripshover
Journal:  Arch Intern Med       Date:  1999 Aug 9-23

8.  Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.

Authors:  P K Jadhav; P Ala; F J Woerner; C H Chang; S S Garber; E D Anton; L T Bacheler
Journal:  J Med Chem       Date:  1997-01-17       Impact factor: 7.446

Review 9.  Salvage treatment against human immunodeficiency virus.

Authors:  M Battegay; T Harr; L Sponagel
Journal:  Ann Med       Date:  1999-08       Impact factor: 4.709

Review 10.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.